Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027 ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I'm still ...

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...

Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, aiming to advance its gene editing technologies targeting ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...